Scientists at Neuroscience 2026 report four studies linking sex differences to Alzheimer's, fibromyalgia and hormone therapy response
Researchers at Neuroscience 2026 reported preliminary evidence that sex and genetic risk shape Alzheimer's disease, fibromyalgia and menopause hormone therapy responses. The findings link menopause, immune activation and gut inflammation to brain outcomes, including differences seen in animal models. Because the reports were presented at a conference and partly rely on rodents, the evidence remains preliminary.
Researchers at Neuroscience 2026 reported evidence that biological sex and genetic risk shape progression and treatment response in Alzheimer's disease and fibromyalgia. The conference presentations described differences in menopause hormone therapy effects, brain circuit vulnerability, immune activation and gut-brain inflammation. The work was presented by scientists studying neurological disorders, and the session was moderated by Liisa Galea of the Center for Addiction and Mental Health. The findings were not released as peer-reviewed papers in the source.
The source said people with genetic risk for Alzheimer's responded differently to menopause hormone therapy than people without that risk, and response varied by hormonal formulation. It also said menopausal rodents with Alzheimer's genetic risk showed particular vulnerability in memory-related brain circuits. In fibromyalgia mouse models, females remained sensitive to touch and showed greater immune activation than males. A mouse model of chronic gut inflammation affected brain function and Alzheimer's-related pathology differently by sex. The source did not provide sample sizes, effect estimates or funding disclosures.
The presentations place sex and genetic risk inside the experimental design, not as background noise. That matters because Alzheimer's affects 35 to 40 million people worldwide, according to the World Health Organization, and fibromyalgia affects 2% to 4% of the global population. The source frames these differences as a route to precision approaches for complex brain disorders, especially when hormone therapy, immune activation and gut inflammation are involved.
The finding matters because Alzheimer's and fibromyalgia involve large patient groups, and treatment choices may depend on sex-specific biology. The source's strongest signal is that menopause hormone therapy effects may depend on genetic risk and formulation, while animal studies point to immune and gut-brain differences. The evidence quality is preliminary: these are conference reports, not peer-reviewed articles in the source, and several findings come from rodents. Human studies with clear endpoints, sample sizes and formulations are needed.
People living with Alzheimer's disease or fibromyalgia, especially women navigating menopause-related treatment choices, are affected because sex and genetic risk may shape disease mechanisms and therapy response.
Sources (1)
- [1]Original source(https://medicalxpress.com/news/2026-11-sex-differences-pain-inflammation-alzheimer.html)